Home Cart Sign in  
Chemical Structure| 55779-48-1 Chemical Structure| 55779-48-1

Structure of Coelenterazine
CAS No.: 55779-48-1

Chemical Structure| 55779-48-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Coelenterazineis is the substrate of many luciferases, as a luciferin, light-emitting molecules, found in many aquatic organisms across eight phyla.

Synonyms: Luciferin (Oplophorus); Preluciferin (Watasenia); Coelenterazine, Coelenterazine

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Coelenterazine

CAS No. :55779-48-1
Formula : C26H21N3O3
M.W : 423.46
SMILES Code : O=C1C(CC2=CC=C(O)C=C2)=NC3=C(CC4=CC=CC=C4)NC(C5=CC=C(O)C=C5)=CN31
Synonyms :
Luciferin (Oplophorus); Preluciferin (Watasenia); Coelenterazine, Coelenterazine
MDL No. :MFCD00467176
InChI Key :LNCOEGVEEQDKGX-UHFFFAOYSA-N
Pubchem ID :135445694

Safety of Coelenterazine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
293T cells 8.3 μM 24 hours PMC3443147
MDA-MB231 cells 10 µM Evaluation of NIR-BRET signal of BBlue2.3 in cells stably expressing iRFP-RLuc8.6-535SG PMC6525985
HEK 293T cells 50 µM Confirm the transcriptional activity of EWSR1-ATF1 PMC5678970
HT29 cells 0.4–12.5 μM 1 hour PMC3443147
C6 rat glioma cells 0.1-200 µg/ml 10 seconds To determine the effects of coelenterazine dose on light yield, showing an approximately linear relationship between 0.1–10 µg/ml and peak signal at 50 µg/ml. PMC117568
C6 rat glioma cells 50 µg/ml 10 seconds To determine the effects of coelenterazine dose on light yield, showing an approximately linear relationship between 0.1–10 µg/ml and peak signal at 50 µg/ml. PMC117568
HeLa cells 10 µM 2 seconds To evaluate the ability of BSA–RuII(CO)2 complex to release CO in HeLa cells, results showed a significant increase in intracellular fluorescence indicating CO release. PMC6525985
COS-7 cells 10 µM To test the inhibitory effect of SIN-1 on the 5-HT transporter (SERT), results showed that SIN-1 concentration-dependently inhibited 5-HT uptake. PMC6525985
KB 8-5-11 Rluc cells 470 nM 6 seconds to 30 minutes To investigate Pgp-mediated transport of Coelenterazine, results showed low bioluminescence in KB 8-5-11 Rluc cells, which could be reversed by Pgp inhibitors. PMC341825
KB 3-1 Rluc cells 470 nM 6 seconds to 30 minutes To investigate Pgp-mediated transport of Coelenterazine, results showed high bioluminescence in KB 3-1 Rluc cells. PMC341825

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
CD-1 mice Subcutaneously implanted C6-Rluc cells Tail-vein injection 0.07-3.5 mg/kg body weight Single injection, lasting 10 minutes To determine the effects of coelenterazine dose on RL signal in vivo, showing a progressive increase in bioluminescence with increasing coelenterazine dose. PMC117568
Nude mice (BALB/c nude mice) Subcutaneous xenograft model Intraperitoneal injection 50 µg Single injection Evaluation of autoluminescence and tumor imaging efficacy of BBlue2.3 in vivo, BBlue2.3 showed lower background signal and higher tumor-specific signal PMC6525985
BALB/c mice Subcutaneous injection of HEK 293T cells and hydrodynamic tail vein injection of plasmids Subcutaneous and intraperitoneal injection 0.1 mM and 0.3 µmol Single injection, observed for 10 minutes Evaluate the bioluminescence performance of new reporters in live mice, showing that teLuc/DTZ was ~54-fold brighter than FLuc/D-luciferin, and Antares2 further improved the signal by 35–90% over teLuc in deep tissues. PMC5678970
Nude mice 293T tumor xenograft model Intraperitoneal injection 80 mg/kg Four doses, immediately after baseline imaging and at 16, 24, and 49 hours To monitor the inhibitory effect of CP9 on Hsp90(α/β)/p23 interactions in live mice, results showed CP9 selectively inhibited Hsp90α/p23 interactions PMC3443147
NCr nu/nu mice KB 3-1 and KB 8-5-11 cell xenograft models Tail vein injection 4 µg/g Single dose, imaging at 2, 6, 8, and 11 minutes post-injection To monitor Pgp transport activity and inhibition via bioluminescence imaging, results showed lower bioluminescence in KB 8-5-11 Rluc tumors compared to KB 3-1 Rluc tumors, which could be reversed by GF120918. PMC341825

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.36mL

0.47mL

0.24mL

11.81mL

2.36mL

1.18mL

23.61mL

4.72mL

2.36mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

[1]Pandey D, Fulton DJ, et al. Molecular regulation of NADPH oxidase 5 via the MAPK pathway. Am J Physiol Heart Circ Physiol. 2011 Apr;300(4):H1336-44.

[2]Ritsick DR, Edens WA, et al. Nox regulation of smooth muscle contraction. Free Radic Biol Med. 2007 Jul 1;43(1):31-8. Epub 2007 Mar 12.

[3]Gentschev I, Stritzker J, et al. Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent. Cancer Gene Ther. 2009 Apr;16(4):320-8.

[4]Bhaumik S, Gambhir SS, et al. Optical imaging of Renilla luciferase reporter gene expression in living mice. Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):377-82. Epub 2001 Dec 18.

[5]Bronsart LL, Stokes C, et al. Chemiluminescence Imaging of Superoxide Anion Detects Beta-Cell Function and Mass. PLoS One. 2016 Jan 11;11(1):e0146601.

[6]Pandey D, Fulton DJ. Molecular regulation of NADPH oxidase 5 via the MAPK pathway. Am J Physiol Heart Circ Physiol. 2011 Apr;300(4):H1336-44. doi: 10.1152/ajpheart.01163.2010. Epub 2011 Feb 4. PMID: 21297032; PMCID: PMC3075021.

[7]Ritsick DR, Edens WA, Finnerty V, Lambeth JD. Nox regulation of smooth muscle contraction. Free Radic Biol Med. 2007 Jul 1;43(1):31-8. doi: 10.1016/j.freeradbiomed.2007.03.006. Epub 2007 Mar 12. PMID: 17561091; PMCID: PMC1989158.

[8]Gentschev I, Stritzker J, Hofmann E, Weibel S, Yu YA, Chen N, Zhang Q, Bullerdiek J, Nolte I, Szalay AA. Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent. Cancer Gene Ther. 2009 Apr;16(4):320-8. doi: 10.1038/cgt.2008.87. Epub 2008 Oct 24. PMID: 18949014.

 

Historical Records

Categories